BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20959375)

  • 1. Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results.
    Heusner TA; Hahn S; Jonkmanns C; Kuemmel S; Otterbach F; Hamami ME; Stahl AR; Bockisch A; Forsting M; Antoch G
    Br J Radiol; 2011 Feb; 84(998):126-35. PubMed ID: 20959375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary lymph node characterization in breast cancer patients using magnetic resonance mammography: a prospective comparative study with FDG PET-CT and healthy women.
    Krammer J; Wasser K; Schnitzer A; Henzler T; Schoenberg SO; Kaiser CG
    Eur J Radiol; 2013 Dec; 82(12):2194-8. PubMed ID: 23993142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer.
    Garcia-Velloso MJ; Ribelles MJ; Rodriguez M; Fernandez-Montero A; Sancho L; Prieto E; Santisteban M; Rodriguez-Spiteri N; Idoate MA; Martinez-Regueira F; Elizalde A; Pina LJ
    Eur Radiol; 2017 Aug; 27(8):3190-3198. PubMed ID: 28004161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
    Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
    J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.
    Scheidhauer K; Walter C; Seemann MD
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S70-9. PubMed ID: 15133634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer.
    Moy L; Noz ME; Maguire GQ; Melsaether A; Deans AE; Murphy-Walcott AD; Ponzo F
    Breast J; 2010; 16(4):369-76. PubMed ID: 20443788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.
    Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D
    Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging--initial findings.
    Stadnik TW; Everaert H; Makkat S; Sacré R; Lamote J; Bourgain C
    Eur Radiol; 2006 Oct; 16(10):2153-60. PubMed ID: 16670863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.
    Finkelstein SE; Carrasquillo JA; Hoffman JM; Galen B; Choyke P; White DE; Rosenberg SA; Sherry RM
    Ann Surg Oncol; 2004 Aug; 11(8):731-8. PubMed ID: 15249335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
    Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
    Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy: clinical results and future perspectives with reference to FDG-PET.
    Nakamura S; Kenjo H; Nishio T; Kazama T; Do O; Suzuki K
    Breast Cancer; 2001; 8(4):351-4. PubMed ID: 11791129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk?
    Rieber A; Schirrmeister H; Gabelmann A; Nuessle K; Reske S; Kreienberg R; Brambs HJ; Kuehn T
    Br J Radiol; 2002 Oct; 75(898):789-98. PubMed ID: 12381687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions.
    Walter C; Scheidhauer K; Scharl A; Goering UJ; Theissen P; Kugel H; Krahe T; Pietrzyk U
    Eur Radiol; 2003 Jul; 13(7):1651-6. PubMed ID: 12835981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.